New at Tetraneuron

News

Spanish biotech Tetraneuron raises more than 2.5 million euros to advance its Alzheimer’s therapy

The biotech company is developing an innovative therapy based on a multifactorial approach to Alzheimer's disease with the potential to slow the progression of the disease. Supported by good preclinical data, Tetraneuron will advance in the regulatory roadmap.

Tetraneuron, resident company of Johnson & Johnson Innovation – JLABS

Tetraneuron, resident company of Johnson & Johnson Innovation – JLABS Tetraneuron, a spin-off of Jose M. Frade’s lab at the Cajal Institute, is a resident company of Johnson & Johnson Innovation – JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling…

XVII EDITION – Farma-Biotech Program

Participation in the XVII edition of the Farma-Biotech Program Different Spanish biotechnology companies and research groups, including Tetraneuron, presented on Wednesday, November, 28, 2018, a total of nine advanced innovative drug development projects to representatives of 17 national and international pharmaceutical companies at a conference organized in Madrid by…

European patent for our Therapy

Therapy: Publication of the European patent grant. On September 5, 2018, the European Patent Office granted the patent for our therapy with No. EP2783696 “Phosphorylation on the Thr-248 and/or Thr-250 residues of transcription factor E2F4 as a therapeutic target in pathological processes associated with somatic polyploidy”. E.U. Patent No. EP2783696B1…

BIOSPAIN 2018

Presenting company in BIOSPAIN 2018 Tetraneuron was selected to make a company presentation during the BIOSPAIN Congress that took place in Seville in September 25-27, 2018 BIOSPAIN is the largest biotech event organized by a national bioindustry association in Europe and one of the largest in the world by the number…

Spanish patent for our Biomarker

Biomarker: Publication of the Spanish patent grant. On October 9, 2017, the Spanish Patent and Trademark Office granted the patent for our biomarker with No. ES2598885 ” Method for determining the risk of developing Alzheimer’s disease”. Spain. Patent No. ES2598885B1…

Tetraneuron in ASEBIO Investor Day

Tetraneuron in ASEBIO Investor Day 2017 Tetraneuron was one of the 30 Spanish biotech start-ups selected to present their project at ASEBIO Investor Day, on September 26-27, 2017 ASEBIO Investor Day is an event which allows Spanish innovative biotechnology projects to be introduced to an audience of leading investors and pharmaceutical…

Tetraneuron presents its Poster at AAIC17

Tetraneuron presents its Poster at AAIC17 Last Monday, July 17th José María Frade, Tetraneuron’s Scientific Director, presented at AAIC17 his Poster: “A Mutant Form of E2F4 Prevents Neuronal Tetraploidization and Cognitive Deficits in 5xFAD Mice without Affecting AB Deposition” The Alzheimer’s Association International Conference 2017 (AAIC17) took place…

Japanese patent for our Therapy

Therapy: Publication of the Japan patent grant. On March 22, 2017, the Japanese Patent Office granted the patent for our therapy with No. 6100276 “Phosphorylation on the Thr-248 and/or Thr-250 residues of transcription factor E2F4 as a therapeutic target in pathological processes associated with somatic polyploidy”. Japan Patent No. JP6100276B2…

New scientific publication of Tetraneuron

Neuronal tetraploidization in the cerebral cortex correlates with reduced cognition in mice and precedes and recapitulates Alzheimer’s-associated neuropathology The study has recently been accepted and published by the prestigious journal Neurobiology of Aging This study demonstrates the existence of neuronal tetraploidization in the cerebral cortex associated with age,…

US patent for our Therapy

Therapy: Publication of the US patent grant. On February 14, 2017, the United States Patent and Trademark Office granted the patent for our therapy with No. 9,567,384 “Phosphorylation on the Thr-248 and/or Thr-250 residues of transcription factor E2F4 as a therapeutic target in pathological processes associated with somatic polyploidy”.